High materiality9/10
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
Why it may matterVerify against the original reporting
buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Sarepta Therapeutics (SRPT) upgraded to Outperform by Wolfe Research; target 27; current price 20.21; indicates upside potential.
- Sarepta upgraded; 27 target; price 20.21; upside potential.
Key facts
- 01
Target: $27
- 02
Posted price: $20.21
- 03
Analyst firm: Wolfe Research
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.